Vicon Industries, Inc. (NYSEMKT:VII) shares moved down -13.66% in last trading session and ended the day at $0.80. VII Gross Margin is 39.90% and its has a return on assets of -18.40%. Vicon Industries, Inc. (NYSEMKT:VII) quarterly performance is -61.76%.
Vicon Industries, Inc. (NYSEMKT:VII) announced that on March 4, 2016, the Company entered into a Credit Agreement with NIL Funding Corporation to provide the Company with a one year $3 million revolving line of credit for working capital purposes.
HP Inc. (NYSE:HPQ) caters to the Technology space. It has a net profit margin of 5.00% and weekly performance is 3.94%. On the last day of trading company shares ended up at $11.42. HP Inc. (NYSE:HPQ) distance from 50-day simple moving average (SMA50) is 10.85%.
HP Inc. (NYSE: HPQ) board of directors has declared a cash dividend of $0.124 per share on the company’s common stock. The dividend, the second in HP Inc.’s fiscal year 2016, is payable on April 6, 2016, to stockholders of record as of the close of business on March 9, 2016.
On 10 March, WidePoint Corp. (NYSEMKT:WYY) shares moved down -2.90% and was closed at $0.67. WYY EPS growth in last 5 year was -51.60%. WidePoint Corp. (NYSEMKT:WYY) year to date (YTD) performance is -3.60%.
WidePoint Corp. (NYSEMKT:WYY) announced that WidePoint has released two new mobile applications that enable the secure creation, delivery, and installation of digital certificates to Android-based mobile devices. The apps, WidePoint Person ID and WidePoint Derived ID, both part of the WidePoint Certificate-on-Device™ solution, make it easy for end-users without specialized knowledge or training to install and use digital certificates on their mobile devices.
Cancer Genetics, Inc. (NASDAQ:CGIX) shares moved up 11.25% in last trading session and ended the day at $2.67. CGIX Gross Margin is 25.30% and its has a return on assets of -47.40%. Cancer Genetics, Inc. (NASDAQ:CGIX) quarterly performance is -8.56%.
On 7 March, Cancer Genetics, Inc. (NASDAQ:CGIX) announced the successful CLIA validation and commercial launch of its next generation sequencing (NGS) assay FOCUS::ONCOMINE™ for solid tumors.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) caters to the Healthcare space. Its weekly performance is -7.73%. On the last day of trading company shares ended up at $30.90. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) distance from 50-day simple moving average (SMA50) is -0.09%.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2015. Cash, cash equivalents and marketable securities totaled $517.5 million on December 31, 2015 compared to $149.1 million on December 31, 2014. The increase in year-end 2015 cash was primarily attributable to the $350 million upfront payment received in December 2015 from BMS for the FPA008 license and collaboration agreement.
Leave a Reply